Clinical trials: Prostate Specific Antigen
PSMA-related Disease, Prostate Cancer
Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients (prostate cancer…
- Conditions
- PSMA-related Disease, Prostate Cancer, Positron Emission Tomography, Metastasis
- Trial name
- NCT06690970
- Testing
- 68Ga/18F-PSMA/PSFA
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Prostate Cancer
Screening for Prostate Cancer Among Those Prostate-specific Antigen Value Between 2.5 and 4.0 ng/mL
The study aims to evaluate the detection rate and characteristics of prostate cancer among males with PSA values between 2.5 and 4.0 ng/mL in Nanjing, meanwhile, to access the effectiveness of conducting multi-parametric MRI…
- Trial name
- NCT04317625
- Testing
- mpMRI scanning
- Where
- China
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)
Prostate cancer remains one of the leading causes of cancer-related morbidity and mortality among men. While PSA-based screening has been associated with reduced prostate cancer mortality, it also results in substantial…
- Trial name
- Visioning III (NCT07762911)
- Testing
- MRI
- Where
- Switzerland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Prostatic Neoplasms
The Application Value of 18F-prostate-specific Membrane Antigen PET/CT in Prostate Cancer
Prostate cancer (PCa) is the most common type of malignant tumor and the third leading cause of cancer-associated mortality among men worldwide.
- Trial name
- NCT04521894
- Testing
- Positron emission tomography/computerized tomography (PET/CT)
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Birth Control
Prostate Specific Antigen (PSA) and Acute Failure Modes Study of the PATH Woman's Condom and FC2 Female Condom
This is a comparative, open-label two-period crossover study of up to 505 couples comparing the PATH Woman's Condom to the FC2 female condom.
- Trial name
- CONRAD-108 (NCT01178840)
- Testing
- WC then FC2, FC2 then WC
- Where
- United States
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- CONRAD
Prostate Carcinoma
Prostate Specific Antigen Levels of Individuals Living in Rural Areas
It was planned in cross-sectional design in order to determine the specific prostate antigen level and some characteristics and the relationship evaluations and prostate specific antigen formation in individuals living in rural…
- Trial name
- NCT06900348
- Testing
- PSA-Activated PSA-PAH1
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- Suleyman Demirel University
Decision Making, Shared, Prostate-Specific Antigen
Promoting Shared-decision Making in Opportunistic Screening for Prostate Cancer
In this project, the investigators aim to evaluate the most appropriate design and implementation strategy of a decision-aid to promote shared-decision making in prostate cancer screening.
- Conditions
- Decision Making, Shared, Prostate-Specific Antigen, Prostate Cancer
- Trial name
- PROSHADE (NCT05187949)
- Testing
- Mixed-method approach
- Volunteers
- 1,781 people, healthy volunteers welcome
- Sponsor
- Universidad Miguel Hernandez de Elche
Prostate Cancer
Combined Prostate-specific Antigen, Multi-parametric MRI and Targeted Prostate Biopsy for Prostate Cancer Screening
The study aims to investigate the incidence of prostate cancer among males in Nanjing and whether a combination of PSA, multi-parametric MRI and targeted biopsy is a feasible approach for screening prostate cancer in China.
- Trial name
- NCT04322045
- Testing
- multi-parametric MRI
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostatic Intraepithelial Neoplasia
A Pilot Study of Lycopene Supplementation in Prostatic Intraepithelial Neoplasia
The purpose of this study is to determine whether dietary lycopene supplementation lowers serum prostate specific antigen(PSA) in men with high grade intraepithelial neoplasia (HGPIN).
- Trial name
- NCT00178113
- Testing
- - Lyc-O-Mato (dietary supplement, 30 mg lycopene/day), - Certagen (multivitamins with minerals)
- Where
- Trinidad and Tobago
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
PSA, Prostate Cancer
Smart Prostate Specific Antigen (PSA) Screening Study
This intervention includes the introduction of the Prostate Cancer Working Group (PCWG )Smart PSA Screening Guidelines and implementation of patient navigation/ care coordination for men with elevated PSA (>4.0 ng/mL).
- Trial name
- NCT04782713
- Testing
- Completing surveys
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Illinois at Chicago
Prostate Cancer
The ProCaRis Study: Prostate Cancer Risk Assessment in General Practice
The preferred method for early detection of prostate cancer (PCa) in older men with family history is the Prostate Specific Antigen test (PSA test), although the method is imprecise.
- Trial name
- ProCaRis (NCT01739062)
- Testing
- Genetic risk assessment
- Where
- Denmark
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Prostate CA
Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study
The prostate specific antigen (PSA) blood test can help diagnose prostate problems, including cancer. The prostate is an organ in the pelvis. It is found in cisgender men, transgender (trans) women and some non-binary people.
- Trial name
- TransPRIDE (NCT06987045)
- Where
- United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Prostate Cancer
Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA
In 22% of patients with elevated Prostate-specific antigen (PSA) MRI guided biopsy will not detect significant prostate cancer (PCA) (defined as either: Gleason score (GS) ≥ 3+4 or tertiary pattern 5, or final stage ≥ pT3a and/or…
- Trial name
- NCT03187990
- Testing
- [68Ga]PSMA-11, [18F]PSMA-1007
- Where
- Switzerland
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Irene Burger
Prostatic Neoplasms
Shared Decision Making for Prostate Cancer Screening: a Practice-Based Randomized Controlled Trial
The purpose of this study is to determine whether an intervention designed to help men share decisions about prostate cancer screening with their physician results in better decision making, more shared decisions, and changes in…
- Trial name
- NCT00630188
- Testing
- You Decide, Reducing Your Risks in the Crash
- Where
- 4 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of North Carolina
Prostate Cancer
Dissemination of Prostate Cancer Screening to PCP's in African American Communities
The aims of this project are to adapt and extend the use of academic detailing to the dissemination of prostate cancer (CaP) screening findings to primary care physicians practicing in African American communities.
- Trial name
- NCT00629330
- Testing
- Academic Detailing
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Columbia University
Prostate Cancer, Risk Assessment
PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria
This study is a pilot trial that builds on findings from the validation of prostate cancer risk calculators in Nigerian men. The goal of the overall study is to improve the early detection of prostate cancer in a high-risk…
- Conditions
- Prostate Cancer, Risk Assessment, Clinical Decision Support Systems, Predictive Value of Tests
- Trial name
- PROACT (NCT07733440)
- Testing
- (a) Training and (b) Supported risk assessment
- Where
- Nigeria
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Ahmadu Bello University
Prostate Cancer Patients Undergoing Radical Prostatectomy, Prostate CA
Research on PSMA-Targeted Intraoperative Fluorescent Imaging Agents
Phase I: Primary Research Objective: Evaluate the safety, tolerability, and pharmacokinetic characteristics of a single dose of DGPR1008 in healthy subjects.
- Trial name
- DGPR1008 (NCT07101354)
- Testing
- 0.01mg/kg DGPR1008 Injection Dose Group 1 (n=6), 0.02mg/kg DGPR1008 Injection Dose Group 2 (n=6), 0.04mg/kg DGPR1008 Injection Dose Group 3 (n=6)
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Haitao Niu, MD
Polycystic Ovary Syndrome
Evaluation of Serum Prostatic Specific Antigen (PSA) After Cyproterone Compound Treatment Compared With Oral Contraceptives Pill in Hirsute Polycystic Ovary Syndrome Patients
The purpose of this study is to evaluate the effect of oral contraceptive on the serum free prostatic specific antigen (PSA)in women with polycystic ovary syndrome(PCOD)compared with cyproterone compound.
- Trial name
- PSA (NCT00955058)
- Testing
- OCP
- Where
- Iran
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University
Prostate Cancer Screening Decision
Prostate Cancer Education in African American Men
This study evaluates the efficacy of a tailored telephone intervention to promote informed decision making about prostate cancer testing among predominantly immigrant black men.
- Trial name
- NCT01415375
- Testing
- Prostate Cancer Screening Education, Fruit and Vegetable Intake Education
- Where
- United States
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- Temple University
Prostatic Diseases
Character Traits and Stress in Suspected Prostate Cancer
It has previously been reported that men with prostate cancer are 1 ) reduced quality of life after diagnosis and treatment, 2 ) neuroticism increases the reduction in QoL related to treatment side effects, and 3) often have very…
- Trial name
- NCT02031029
- Where
- 2 sites in Norway
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Helse Stavanger HF